Ratification delay in Germany and the spectre of UK non-participation mean many believe the project will quietly be dropped - but to do so would be a serious mistake
Secret government documents detailing pharma patent discussions between UK and US officials have stirred up a controversy in the run up to the British general election later this month
Read more
Strategies employed not only by rights owners but also by those opposing their grants will need to be recalibrated to reflect the new realities
Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms
Read more
Design protection has taken on an increasingly important role in recent years, since appearance and exterior shape now play a fundamental role in the success of a product. Designs are now relevant to a wide range of products involving industry,…
Read more
A new financing and advisory mechanism to help innovative European SMEs secure high-quality patents and build effective portfolios will be rolled out across Europe in 2019, it was revealed today. The creation of Patent Factory Europe (PFE) was… Read more
With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem
Read more
With so many issues emerging across the entire supply chain, the sector’s IP leaders will be sharing their thoughts and insights at events in Detroit and Munich next month
Read more
In an exclusive opinion piece for IAM, Jim Beveridge of the Innovators' Network argues that originators need to embrace transparency and avoid royalty stacking to allow IoT innovation to thrive
Read more
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016
Read more
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016
Read more
The Labour Party – the main opposition to Boris Johnson’s Conservatives – recently set out a radical plan to change the patent regime for life sciences innovators
Read more
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016
Read more
The Labour Party – the main opposition to Boris Johnson’s Conservatives – recently set out a radical plan to change the patent regime for life sciences innovators
Read more
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016
Read more
Sisvel has announced two deals with Samsung that confirm the IP mangement and licensing platform’s continued progress into the top division of the patent monetisation space. Not only has the Korean giant agreed to take a royalty-bearing licence to a… Read more
A company described as a new-style European patent troll has told IAM that it believes a deal with a large pharma company is likely at some point this year. The organisation, which has used a provision in the European Patent Convention to make… Read more
With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem
Read more
In an exclusive opinion piece for IAM, Jim Beveridge of the Innovators' Network argues that originators need to embrace transparency and avoid royalty stacking to allow IoT innovation to thrive
Read more
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016
Read more
Europe’s highest court has refused to tackle a long-standing question relating to third-party marketing approval, while its Advocate General has provided confusing guidance on Article 3(a)
Read more
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016
Read more
The news that António Campinos has been chosen to succeed Benoît Battistelli as president of the European Patent Office should not have come as a huge surprise to IAM’s readers. We predicted it might happen back in July. But the speed of the… Read more
Last week the European Commission published a Brexit position paper on dealing with intellectual property issues raised by the UK’s departure from the European Union – which is scheduled to happen at the end of March 2019. The paper focused on… Read more
Suspension of the probe may not herald a broader deal, but it does underscore the significant legislative concessions China has made on tech transfer and other IP issues
Read more
With so many issues emerging across the entire supply chain, the sector’s IP leaders will be sharing their thoughts and insights at events in Detroit and Munich next month
Read more
The German company's divestiture to Elanco is the latest example of a pharma giant fleeing non-core business areas - and it is unlikely to be the last
Read more
@IAM_magazine RT @grupobioceres: #IPBCGlobal #IntellectualProperty
📌 Gloria Montaron Estrada, our Director of Legal Affairs and Intellectual Property wil… Read more
We use cookies on www.iam-media.com. By using this site, you agree that we may store and access cookies on your device. For further information please read our cookie policy and our terms and conditions.
